大学院生が筆頭著者の論文と学位論文

大学院生が研究室に残り博士研究員/助教として発表した論文も含む。

Yamamoto, K. et al. (2020) A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. Cell Rep. 24;36(8):109576


Fujino, T. et al. (2020) Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cell through activation of Akt/mTOR pathway. Nat Commun. 12:1826


Hayashi, Y. et al. (2020) Impaired osteoblastic differentiation of MSCs suppresses normal hematopoiesis in MDS. Cell Stem Cell in revise.


Takeda, R., Asada, S. et al. (2020) HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood 136:1670-1684.


Fukushima, T. et al. (2019) Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium. Cell Rep. 29:4144-4158.


Hayashi, Y. et al. (2019) Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nat Commun. 10:4869.


Tamura, M. et al. (2019) Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. Sci Rep. 9:8171.


Saika, M. et al. (2018) ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation. Sci Rep. 8:15873.


Yonezawa, T. et al. (2018) The ubiquitin ligase RNF38 promotes RUNX1 ubiquitination and enhances RUNX1-mediated suppression of erythroid transcription program. Biochem Biophys Res Commun. 505:905-909.


Asada, S. et al. (2018) Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 9:2733.


Nagase, R. et al. (2018) Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. J Exp Med. 215:1729-1747.


Inoue, D. et al. (2018) A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies. Leukemia. 32:1327-1337.


Isobe, M. et al. (2018) The CD300e molecule in mice is an immune-activating receptor. J. Biol. Chem. 293:3793-3805.


Maehara, A. et al. (2018) Role of the ceramide-CD300f interaction in gram-negative bacterial skin infections. J. Invest. Dermatol. 138:1221-1224.


Miyashita, K. et al. (2018) Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. Biochem. Biophys. Res. Commun. 495:2310-2316.


Izawa, K. et al. (2017) Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment. Sci. Rep. 7:4298.


Yonezawa, T. et al. (2017) The ubiquitin ligase STUB1 regulates stability and activity of RUNX1 and RUNX1-RUNX1T1. J. Biol. Chem. 292:12528-12541.


Shiba, E. et al. (2017) Ceramide-CD300f binding inhibits lipopolysaccharide-induced skin inflammation. J. Biol. Chem. 292:2924-2932.


Inoue, D. et al. (2016) Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp. Hematol. 44:172-176.


Inoue, D. et al. (2015) UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia.29:847-857.


Matsukawa, T. et al. (2015) Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation. Gut. 65:777-787.


Togami, K. et al. (2015) A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm. Exp. Hematol. 43:300-308.


Inoue, D. et al. (2015) SETBP1 mutations drive leukemic transformation in ASXL1-murtated MDS. Leukemia. 29:2257-2260.


Izawa, K. et al. (2014) Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast-cell activation. J Allergy Clin Immunol. 133:270-3.e1-7.


Uchida, T. et al. (2014) Hes1 up-regulation contributes to the development of FIP1L1-PDGFRA-positive leukemia in blast crisis. Exp. Hematol. 42:369-379.


Oki, T. et al. (2014) A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition. Sci Rep. 4:4012.


Nakahara, F. et al. (2014) Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. Blood. 123:3932-3942.


Ishihara, J. et al. (2014) Nov/CCN3 regulates long-term repopulating activity of murine hematopoietic stem cells via integrin αvβ3. Int J Hematol. 99:393-406.


Inoue, D. et al. (2013) Myelodysplastic syndromes are induced by histone methylation?altering ASXL1 mutations. J. Clin. Invest.123:4627-4640.


Nishimura, K. et al. (2013) APCCDH1 targets MgcRacGAP for destruction in the late M phase. Plos One. 8:e63001.


Takahashi, M. et al. (2013) Human CD300C delivers an Fc receptor-g-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition. J. Biol. Chem. 288:7662-6775.


Izawa, K. et al. (2012) LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide. Immunity. 37:827-839.


Kagiyama, Y. et al. (2012) Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML-ETO-positive leukemia in mice. Int. J. Hematol. 96:638-48.


Yamanishi, Y. et al. (2012) A soluble form of LMIR5/CD300b amplifies lipppolisaccharide-induced lethal inflammation in sepsis. J. Immunol. 189:1773-9.


Doki, N. et al. (2012) Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models. Int. J. Hematol. 95:167-75.


Nakamura, M. et al. (2012) TSC-22 is a negative-feedback regulator of Ras/Raf signaling: Implications for tumorigenesis. Cancer Science. 103:26-33.


Oki, T. et al. (2011) Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis. Leukemia. 26:1038-1045.


Enomoto, Y. et al. (2011) Em/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 25:1849-1856.


Enomoto, Y. et al. (2010) Characterization of leukocyte mono-Ig receptor 7 (LMIR7)/CLM3 as an activating receptor: Its similarities to and differences from LMIR4/CLM5. J. Biol. Chem. 285:35274-35283.


Minobe, K. et al. (2010) Expression of ADAMTS4 in Ewing's sarcoma.Int J Oncol. 37:569-81.


Yamanishi, Y. et al. (2010) TIM1 is an endogenous ligand for LMIR5/CD300b and LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury. J. Exp. Med. 207:1501-1511.


Nakahara, F. et al. (2010) Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogeneou leukemia. Blood. 115:2872-2881.


Kawashima, T. et al. (2009) A Rac GTPase activating protein MgcRacGAP is an NLS-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell Biol. 29:1796-1813.


Izawa, K. et al. (2009) Activating and inhibitory signals from an inhibitory receptor LMIR3/CLM-1: LMIR3 augments LPS response through association with FcRg in mast cells. J. Immunol. 183:925-936.


Doki, N. et al. (2009) A Rac GTPase activating protein MgcRacGAP is constitutively phosphorylated on serine 387 in the v-Src-transformed NIH3T3 cells. Cancer Science. 100:1675-1679.


Oki, T. et al. (2009) Evidence that integrin alpha 2b beta 3-dependent interaction of mast cells with fibrinogen exacerbates chronic inflammation. J. Biol. Chem. 284:31463-31472.


Ono, R. et al. (2009) Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia. 23:2197-2209.


Watanabe-Okochi, N. et al. (2008) AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Int J. Hematology. 89:470-481.


Yamanishi, Y. et al. (2008) Analysis of mouse LMIR5/CLM7 as an activating receptor: differential regulation of LMIR5/CLM7 between mouse and human. Blood. 111:688-698.


Hiwatari, M. et al. (2008) Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23). Leukemia. 22:2279-2280.


Sugano, Y. et al. (2008) Blood. 111:1167-1172.


Izawa, K. et al. (2007) Functional analysis of an activating receptor LMIR4 as a counterpart of an inhibitory receptor LMIR3. J. Biol. Chem. 25:17997-18008.


Lu, Y. et al. (2007) Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD. Leukemia. 21:2246-2257.


Oki, T. et al. (2006) Integrin alpha-IIb-beta-3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J. Immunol. 176:52-60.


Kawashima, T. et al. (2006) Rac1 and a GTPase activating protein MgcRacGAP are required for nuclear translocation of STAT transcription factors. J. Cell Biol. 175:937-946.


Ono, R. et al. (2005) Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple lineage leukemogenesis. J Clin. Invest. 115:919-929.


Urano, A. et al. (2005) Infertility with defective spermiogenesis in mice lacking AF5q31, the target of chromosomal translocation in human infant leukemia. Mol. Cell. Biol. 15:6834-6845.


Minoshima, Y. et al. (2005) The constitutive centromere component CENP-50 is required for recovery from spindle damage. Mol. Cell. Biol. 25:10315-10328.


Ono, R. et al. (2005) Disruption of Sept6, a fusion partner gene of Mixed Lineage Leukemia (MLL), does not affect the ontogeny, leukemogenesis induced by MLL-SEPT6, or the phenotype induced by the loss of Sept4. Mol. Cell. Biol. 25:10965-10978.


Tonozuka, Y. et al. (2004) A GTPase activating protein binds STAT3 and is required for IL-6-induced STAT3 activation and differentiation of a leukemic cell line. Blood. 104:3550-3557.


Ikeda, Y. et al. (2004) Vasorin, a novel TGF-beta binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc. Natl. Acad. Sci. USA. 101:10732-10737.


Minoshima, Y. et al. (2003) Phosphorylation by Aurora B converts MgcRacGAP to a RhoGAP during cytokinesis. Dev Cell. 4:549-560.


Hirose, K. et al. (2001) MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody. J. Biol. Chem. 276:5821-5828.


Kawashima, T. et al. (2001) STAT5 induces macrophage differentiation of M1 leukemia cells through activation of IL-6 production mediated by NF- B p65. J. Immunol. 167:3652-3660.


Tonozuka, Y. et al. (2001) Molecular cloning of a human novel type I cytokine receptor related to Delta1. Cytogenetics and Cell Genetics. 93:23-25.


Yamada, K. et al. (2000) Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int. J. Hematol. 71:46-54.


Fujio, K. et al. (2000) Molecular cloning of a novel type I cytokine receptor similar to the common gamma chain. Blood. 95:2204-2211.


Misawa, K. et al. (2000) Molecular cloning and characterization of a mouse homolog of human TNFSF14, a member of the TNF superfamily. Cytogenetics and Cell Genetics. 89:89-91.


Misawa, K. et al. (2000) A method to identify cDNAs based on localization of green fluorescent protein fusion products. Proc. Natl. Acad. Sci. U.S.A. 97:3062-3066.


Morita, S. et al. (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Therapy. 7:1063-1066.


Fujio, K. et al. (2000) Functional reconstitution of Class-II MHC-restricted T cell immunity mediated by retroviral transfer of the αβTCR complex. J. Immunol. 165:528-533.


Kojima, T. et al. (2000) Troy, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles. J. Biol. Chem. 275:20742-20747.


Ariyoshi, K. et al. (2000) Constitutive activation of STAT5 by a point mutation in the SH2 domain. J. Biol. Chem. 275:24407-24413.


Kawashima, T. et al. (2000) MgcRacGAP is involved in the control of growth and differentiation of hematopoietic cells. Blood. 96:2116-2124.


Sugiyama, T. et al. (2000) A novel low-density lipoprotein receptor-related protein mediating cellular uptake of apolipoprotein E-enriched beta-VLDL in vitro. Biochemistry. 39:15817-15825.


Kojima, T. et al. (1999) A signal sequence trap based on a constitutively active cytokine receptor. Nat. Biotechnol. 17:487-490.